Reply

We appreciate the constructive comments provided by Allain Braillon on our study evaluating the incidence of disease progression in patients with hepatitis C virus (HCV) infection who underwent direct-acting antiviral (DAA) treatment.1 Essentially, he highlighted a relevant observation of our study and requested clarification on some issues related to the analysis of the Latin American Liver Research, Educational and Awareness Network cohort.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research